Testing LM-168 with or without toripalimab for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This study tests a new drug called LM-168, either alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that haven't responded to standard treatments. It aims to see if this combination is safe and effective, and may offer a new option when others have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have an advanced solid tumor that standard treatments no longer help or you can't take them.
- You must be well enough to be up and about (ECOG 0 or 1), with a life expectancy of at least 3 months.
- You must be willing to provide a tumor sample (either from a past biopsy or a new one) — this is optional but helpful.
- You should not have had immunotherapy that you had to stop because of severe side effects.
- You must not have active brain metastases, autoimmune disease, or other major uncontrolled health issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new experimental drug, LM-364, given alone or with other cancer treatments for people with advanced solid tumors. It aims to see if the drug is safe and effective.
This trial tests a new drug called LM-168, either alone or combined with another cancer treatment, for people with advanced solid tumors that have not responded to standard therapies. The goal is to see if it can shrink tumors or slow their growth.
This trial tests a new combination of two drugs (LTC004 and toripalimab) for people with advanced solid tumors that have stopped responding to standard immunotherapy. It aims to see if this combination can help when immunotherapy alone no longer works.
This study tests a combination of two drugs (LM-108 and toripalimab) for people with advanced solid tumors that have a specific marker called MSI-H or dMMR. It is for those whose cancer has grown after previous immunotherapy treatment.
This trial tests a new drug, LM-2417, for people with advanced solid tumors that have come back or not responded to treatment. The study will see if LM-2417 is safe and effective, possibly as a new option for those who have run out of standard therapies.
This trial tests a new combination of two drugs (AL8326 and Toripalimab) for people with advanced solid tumors that have stopped responding to standard treatments or have no other options. The goal is to see if the combination is safe and shrinks tumors.
Hear when a new Advanced Solid Tumours trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.